Composition and method for increasing the anabolic state of muscle cells
View Patent ↗A nutritional supplement comprising at least a therapeutically effective amount of ethyl pyruvate and a therapeutically effective amount of at least one α-hydroxy branched-chain amino acid metabolite is provided by the present invention. The ingredients of the present nutritional supplement substantially simultaneously act to induce a anabolically-favorable state for muscle by substantially simultaneously maintaining blood and muscle physiological pH levels as well as increasing cellular concentrations of branched-chain amino acids. Both a composition and a method are provided by the present disclosure.
1. A composition for causing an anabolically-favorable state for muscle in a mammal, comprising ethyl pyruvate and at least one α-hydroxy branched-chain amino acid metabolite.
2. The composition of claim 1 , wherein the α-hydroxy branched-chain amino acid metabolite is selected from the group consisting of α-hydroxyisocaproic acid, α-hydroxy-β-methylvaleric acid, and α-hydroxy-isovaleric acid.
3. The composition of claim 1 wherein the ethyl pyruvate and the α-hydroxy branched-chain amino acid metabolite are part of a solid oral dosage form having a multi-phasic rate of dissolution.
4. The composition of claim 3 wherein said multi-phasic rate of dissolution comprises a first-phase and a second-phase; whereby said first-phase has a first rate of dissolution said second-phase has a second rate of dissolution.
5. The composition of claim 4 , wherein the multi-phasic rate of dissolution provides a time-release mechanism.
6. The composition of claim 4 , further comprising a third-phase, whereby said third-phase has a third rate of dissolution.
7. The composition of claim 5 , wherein the multi-phasic rate of dissolution provides a time-release mechanism.
8. A method for causing an anabolically-favorable state of muscle in a mammal, comprising at least the step of administering to the mammal a composition comprising ethyl pyruvate and at least one α-hydroxy branched-chain amino acid metabolite.
9. The method of claim 8 , wherein the .alpha.-hydroxy branched-chain amino acid metabolite is selected from the group consisting of α-hydroxyisocaproic acid, α-hydroxy-β-methylvaleric acid, and α-hydroxy-isovaleric acid.
10. The method of claim 8 wherein the ethyl pyruvate and the α-hydroxyisocaproic acid are part of a solid oral dosage form having a multi-phasic rate of dissolution.
11. The method of claim 10 wherein said multi-phasic rate of dissolution comprises a first-phase and a second-phase; whereby said first-phase has a first rate of dissolution said second-phase has a second rate of dissolution.
12. The method of claim 10 , wherein the multi-phasic rate of dissolution provides a time-release mechanism.
13. The method of claim 11 , further comprising a third-phase, whereby said third-phase has a third rate of dissolution.
14. The method of claim 13 , wherein the multi-phasic rate of dissolution provides a time-release mechanism.